AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7631635 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of male patients always using condoms for anal sex
Number of subjects: 0
Study 7631635 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of male patients always using condoms for vaginal sex
Number of subjects: 0
Study 7631635 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of male patients always using condoms for oral sex
Number of subjects: 0
Study 2190850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (10 mg four times a day for 8 or 16 weeks)
Number of subjects: 19
Study 2190850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 7010854 — intervention group
Group type: COMPARATOR
Intervention: 200 mg of metoprolol plus placebo
Number of subjects: 119
Study 7010854 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of metoprolol plus 25 mg of hydrochlorothiazide
Number of subjects: 119
Study 7010854 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of metoprolol plus 50 mg hydrochlorothiazide
Number of subjects: 119
Study 7010854 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg metoprolol plus 50 mg of hydralazine
Number of subjects: 119
Study 31390500 — intervention group
Group type: EXPERIMENTAL
Intervention: Volanesorsen
Number of subjects: 66
Study 31390500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 27198535 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Eats web‐based intervention
Number of subjects: 126
Study 27198535 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study 27198535 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 126
Study 25814051 — intervention group
Group type: EXPERIMENTAL
Intervention: Sport students (SLS)
Number of subjects: 114
Study 25814051 — intervention group
Group type: COMPARATOR
Intervention: Dental students (ZMS)
Number of subjects: 114
Study 23484100 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosteum (27 mg natural genistein, 200 IU cholecalciferol, 20 mg citrated zinc bisglycinate)
Number of subjects: 30
Study 23484100 — intervention group
Group type: COMPARATOR
Intervention: Squadrito formulation (27 mg natural genistein, 400 IU cholecalciferol, 500 mg elemental calcium)
Number of subjects: 30
Study 23484100 — intervention group
Group type: EXPERIMENTAL
Intervention: Citracal Plus Bone Density Builder (27 mg synthetic genistein, 600 mg elemental calcium, 400 IU vitamin D3, 50 mg magnesium, 7.5 mg zinc, 1 mg copper, 75 μg molybdenum, 250 μg boron)
Number of subjects: 30
Study 19892506 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based lectures
Number of subjects: 44
Study 19892506 — intervention group
Group type: COMPARATOR
Intervention: Classroom lectures
Number of subjects: 44
Study 19892506 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based lectures (in residents without prior training)
Number of subjects: 44
Study 19892506 — intervention group
Group type: COMPARATOR
Intervention: Classroom lectures (in residents without prior training)
Number of subjects: 44
Study 19892506 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based lectures (in residents with prior training)
Number of subjects: 44
Study 19892506 — intervention group
Group type: COMPARATOR
Intervention: Classroom lectures (in residents with prior training)
Number of subjects: 44
Study 19850257 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting stent (ZES)
Number of subjects: 477
Study 19850257 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 477
Study 17010305 — intervention group
Group type: EXPERIMENTAL
Intervention: Left alone (boredom)
Number of subjects: 40
Study 17010305 — intervention group
Group type: EXPERIMENTAL
Intervention: Solving maths problems (frustration)
Number of subjects: 40
Study 17010305 — intervention group
Group type: COMPARATOR
Intervention: Reprimanded for nail biting (contingent attention)
Number of subjects: 40
Study 17010305 — intervention group
Group type: COMPARATOR
Intervention: Continuous conversation (noncontingent attention)
Number of subjects: 40
Study 15006845 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of triamcinolone acetonide (4 mg)
Number of subjects: 151
Study 15006845 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 11342699 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-release formulation of L-dopa plus benserazide
Number of subjects: 16
Study 11342699 — intervention group
Group type: COMPARATOR
Intervention: Slow-release formulation of L-dopa plus benserazide
Number of subjects: 16
Study 9040213 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus calcium (1.0 g/day) and vitamin D (32,000 IU/wk) supplementation
Number of subjects: 14
Study 9040213 — intervention group
Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 14
Study 9040213 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus calcium and vitamin D supplementation
Number of subjects: 14
Study 7713100 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 2.5 mg b.i.d.
Number of subjects: 55
Study 7713100 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 5 mg b.i.d.
Number of subjects: 55
Study 7713100 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 10 mg b.i.d.
Number of subjects: 55
Study 7713100 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg.day-1
Number of subjects: 55
Study 7713100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 2455118 — intervention group
Group type: EXPERIMENTAL
Intervention: nifedipine (10 mg p.o.)
Number of subjects: 11
Study 2455118 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 11
Study 29329042 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (4g/day)
Number of subjects: 56
Study 29329042 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 27035372 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapy for depression (3 months duration)
Number of subjects: 217
Study 24901821 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-222 + telaprevir (DUAL regimen; n=47)
Number of subjects: 152
Study 24901821 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-222 + telaprevir + ribavirin (TRIPLE regimen; n=46)
Number of subjects: 152
Study 24901821 — intervention group
Group type: EXPERIMENTAL
Intervention: VX-222 + peginterferon + ribavirin (QUAD regimen; n=59)
Number of subjects: 152
Study 22902522 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil supplementation (3g/day)
Number of subjects: 16
Study 22902522 — intervention group
Group type: COMPARATOR
Intervention: Placebo oil
Number of subjects: 16
Study 20059568 — intervention group
Group type: EXPERIMENTAL
Intervention: Four quarterly bonus checks
Number of subjects: 179
Study 20059568 — intervention group
Group type: COMPARATOR
Intervention: Single year-end bonus (maximum of U.S.$5,000/year)
Number of subjects: 179
Study 18708832 — intervention group
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen (2 liters/minute)
Number of subjects: 389
Study 18708832 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplemental oxygen)
Number of subjects: 389
Study 16820403 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 16
Study 16820403 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 14563968 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct abciximab therapy (0.25 mg/kg bolus and 12-hour infusion of 0.125 microg x kg(‐1) x min(‐1))
Number of subjects: 50
Study 14563968 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunct abciximab therapy
Number of subjects: 50
Study 14563968 — intervention group
Group type: COMPARATOR
Intervention: Standard antithrombotic therapy (aspirin, clopidogrel, and heparin)
Number of subjects: 50
Study 14563968 — intervention group
Group type: COMPARATOR
Intervention: Filter protection
Number of subjects: 50
Study 14563968 — intervention group
Group type: EXPERIMENTAL
Intervention: Both abciximab and filter protection
Number of subjects: 50
Study 10891434 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgrastim (10 microg/kg daily)
Number of subjects: 54
Study 10891434 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 8882027 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 15
Study 8882027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 1546139 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide (150 mg t.i.d.)
Number of subjects: 0
Study 1546139 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (600 mg t.i.d.)
Number of subjects: 0
Study 4074610 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 8
Study 4074610 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 8
Study 29676440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib (1.3 mg/m2/dose)
Number of subjects: 25
Study 27562403 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (lipopolysaccharide)
Number of subjects: 16
Study 24292896 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person delivery of genomic risk results from a genetic counselor
Number of subjects: 300
Study 24292896 — intervention group
Group type: COMPARATOR
Intervention: Online delivery of genomic risk results through the testing company's website
Number of subjects: 300
Study 24292896 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall preference for receiving results online
Number of subjects: 300
Study 24292896 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust levels among participants with increased genetic risk
Number of subjects: 300
Study 21750974 — intervention group
Group type: EXPERIMENTAL
Intervention: CHO gel ingestion
Number of subjects: 11
Study 20733443 — intervention group
Group type: EXPERIMENTAL
Intervention: Titrated oral misoprostol
Number of subjects: 231
Study 20733443 — intervention group
Group type: COMPARATOR
Intervention: Intravenous oxytocin
Number of subjects: 231
Study 19116007 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural rehabilitation
Number of subjects: 125
Study 19116007 — intervention group
Group type: COMPARATOR
Intervention: Primary care
Number of subjects: 125
Study 16026367 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.045 mg
Number of subjects: 210
Study 16026367 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.225 mg
Number of subjects: 210
Study 16026367 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.45 mg
Number of subjects: 210
Study 16026367 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Number of subjects: 210
Study 16026367 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.75 mg
Number of subjects: 210
Study 16026367 — intervention group
Group type: COMPARATOR
Intervention: Metformin 1000 mg
Number of subjects: 210
Study 16026367 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (all doses)
Number of subjects: 210
Study 16026367 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 210
Study 16026367 — intervention group
Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 210
Study 12450642 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (50 mg orally)
Number of subjects: 31
Study 12450642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 10579141 — intervention group
Group type: EXPERIMENTAL
Intervention: Alprazolam
Number of subjects: 59
Study 10579141 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 59
Study 10579141 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 59
Study 10579141 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole and Itraconazole
Number of subjects: 59
Study 10579141 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampin, Carbamazepine, and Phenytoin
Number of subjects: 59
Study 8600189 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 71
Study 8600189 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT
Number of subjects: 71
Study 8600189 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise + HRT
Number of subjects: 71
Study 8600189 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 71
Study 1725914 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 298
Study 1725914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 1725914 — intervention group
Group type: EXPERIMENTAL
Intervention: Not specified (patients without ischemia)
Number of subjects: 298
Study 6352659 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime
Number of subjects: 48
Study 6352659 — intervention group
Group type: COMPARATOR
Intervention: Combination of cephalothin, carbenicillin and gentamicin
Number of subjects: 48
Study 31302943 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Tranexamic Acid (TA) 1,500 mg daily for 6 weeks
Number of subjects: 40
Study 31302943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 29869380 — intervention group
Group type: EXPERIMENTAL
Intervention: BMW guidewire
Number of subjects: 0
Study 29869380 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot 50 guidewire
Number of subjects: 0
Study 29869380 — intervention group
Group type: COMPARATOR
Intervention: Pressure ≤12 atm
Number of subjects: 0
Study 29869380 — intervention group
Group type: COMPARATOR
Intervention: Pressure >12 atm
Number of subjects: 0
Study 27083496 — intervention group
Group type: EXPERIMENTAL
Intervention: MeDiet-nuts
Number of subjects: 520
Study 27083496 — intervention group
Group type: EXPERIMENTAL
Intervention: MeDiet-EVOO
Number of subjects: 520
Study 27083496 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 520
Study 24898236 — intervention group
Group type: EXPERIMENTAL
Intervention: Breakfast group
Number of subjects: 309
Study 24898236 — intervention group
Group type: EXPERIMENTAL
Intervention: No Breakfast (NB) group
Number of subjects: 309
Study 24898236 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 309
Study 22621626 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 100 mg daily
Number of subjects: 402
Study 22621626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 402
Study 20150175 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic-activated cell sorting (MACS) for sperm preparation (D + M)
Number of subjects: 60
Study 20150175 — intervention group
Group type: COMPARATOR
Intervention: Conventional density gradient centrifugation (DGC)
Number of subjects: 60
Study 17367362 — intervention group
Group type: EXPERIMENTAL
Intervention: J-shaped active fixation (AF) leads
Number of subjects: 200
Study 17367362 — intervention group
Group type: COMPARATOR
Intervention: J-shaped passive fixation (PF) leads
Number of subjects: 200
Study 15465628 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment with guanine nucleotides (GTP)
Number of subjects: 0
Study 15465628 — intervention group
Group type: COMPARATOR
Intervention: Endogenous GAL
Number of subjects: 0
Study 11595248 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 35
Study 11595248 — intervention group
Group type: COMPARATOR
Intervention: Health education control (CTL)
Number of subjects: 35
Study 9637638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil at a dosage of 0.1 microg kg(‐1) x min(‐1) until skin closure
Number of subjects: 19
Study 7986280 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethyl alcohol 0.55‐0.66 g/kg
Number of subjects: 10
Study 7986280 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood alcohol levels > 100 mg/100 ml
Number of subjects: 10
Study 7986280 — intervention group
Group type: COMPARATOR
Intervention: Baseline measurements
Number of subjects: 10
Study 2904218 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg pirenzepine
Number of subjects: 16
Study 2904218 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg famotidine
Number of subjects: 16
Study 2904218 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine
Number of subjects: 16
Study 2904218 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg famotidine plus 50 mg pirenzepine
Number of subjects: 16
Study 2904218 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine plus 50 mg pirenzepine
Number of subjects: 16
Study 31057137 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-check-in kiosk
Number of subjects: 100
Study 31057137 — intervention group
Group type: COMPARATOR
Intervention: Routine nurse-initiated patient identification
Number of subjects: 100
Study 28291572 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine 60mg
Number of subjects: 19
Study 25925842 — intervention group
Group type: EXPERIMENTAL
Intervention: edoxaban 15 mg once daily
Number of subjects: 50
Study 25925842 — intervention group
Group type: COMPARATOR
Intervention: edoxaban 30 mg once daily
Number of subjects: 50
Study 25925842 — intervention group
Group type: COMPARATOR
Intervention: edoxaban 60 mg once daily
Number of subjects: 50
Study 22153756 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Patient Profile‐Prostate (decision support system)
Number of subjects: 494
Study 22153756 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual patient education)
Number of subjects: 494
Study 21756812 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone (5 mg diluted in 5 ml normal saline inhaled every 8 hours for two days pre-operation)
Number of subjects: 30
Study 21756812 — intervention group
Group type: COMPARATOR
Intervention: Control (10 ml normal saline inhaled)
Number of subjects: 30
Study 19637941 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate 200 mg once/day
Number of subjects: 25
Study 19637941 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg twice/day
Number of subjects: 25
Study 19637941 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol succinate (various doses: 25, 50, 100, 200 mg once/day)
Number of subjects: 25
Study 19637941 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol (various doses: 3.125, 6.25, 12.5, 25 mg twice/day)
Number of subjects: 25
Study 15809216 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy
Number of subjects: 0
Study 15809216 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation (PMR)
Number of subjects: 0
Study 15809216 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study 10357747 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 or 120 mg Fe plus 3.5 mg folic acid weekly for 22 weeks
Number of subjects: 624
Study 10357747 — intervention group
Group type: COMPARATOR
Intervention: 5 mg folic acid weekly
Number of subjects: 624
Study 8540545 — intervention group
Group type: EXPERIMENTAL
Intervention: Argon laser trabeculoplasty
Number of subjects: 271
Study 8540545 — intervention group
Group type: COMPARATOR
Intervention: Topical medication
Number of subjects: 271
Study 2036794 — intervention group
Group type: EXPERIMENTAL
Intervention: Copper-bearing Lippes Loop IUD
Number of subjects: 371
Study 2036794 — intervention group
Group type: COMPARATOR
Intervention: Standard Lippes Loop IUD
Number of subjects: 371
Study 7012343 — intervention group
Group type: EXPERIMENTAL
Intervention: Group counseling and education (12 weekly sessions)
Number of subjects: 0
Study 7012343 — intervention group
Group type: COMPARATOR
Intervention: Educational session (for both groups)
Number of subjects: 0
Study 29401177 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg oral)
Number of subjects: 52
Study 29401177 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 29418049 — intervention group
Group type: EXPERIMENTAL
Intervention: SBIRT program (brief motivational intervention on alcohol use and referral to specialized treatment)
Number of subjects: 200
Study 29418049 — intervention group
Group type: COMPARATOR
Intervention: Control group (two leaflets regarding alcohol use and study protocol)
Number of subjects: 200
Study 26827116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide BID (10μg, 12-30 weeks)
Number of subjects: 4625
Study 26827116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QW (2mg, 24-30 weeks)
Number of subjects: 4625
Study 24573743 — intervention group
Group type: EXPERIMENTAL
Intervention: TSU-68 + SOX
Number of subjects: 105
Study 24573743 — intervention group
Group type: COMPARATOR
Intervention: SOX
Number of subjects: 105
Study 22663011 — intervention group
Group type: EXPERIMENTAL
Intervention: trametinib (2 mg orally once daily)
Number of subjects: 322
Study 22663011 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy (intravenous dacarbazine 1000 mg/m² or paclitaxel 175 mg/m² every 3 weeks)
Number of subjects: 322
Study 22663011 — intervention group
Group type: EXPERIMENTAL
Intervention: trametinib
Number of subjects: 322
Study 22663011 — intervention group
Group type: COMPARATOR
Intervention: chemotherapy
Number of subjects: 322
Study 20637666 — intervention group
Group type: EXPERIMENTAL
Intervention: EyeSpy with occlusive eyepatch
Number of subjects: 72
Study 20637666 — intervention group
Group type: EXPERIMENTAL
Intervention: EyeSpy with red-blue dissociative goggles
Number of subjects: 72
Study 20637666 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Visual Acuity (EVA) tester and stereopsis testing
Number of subjects: 72
Study 20637666 — intervention group
Group type: COMPARATOR
Intervention: Professional eye examination
Number of subjects: 72
Study 17985560 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA application four times over a two week period starting with beginning reinnervation of the fingers
Number of subjects: 0
Study 17985560 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study 15854844 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic three-dimensional non-rigid registration scheme using self-organizing maps (SOMs) and radial basis functions (RBFs) for thoracic CT data.
Number of subjects: 15
Study 15854844 — intervention group
Group type: EXPERIMENTAL
Intervention: Estimation of lung tumor volumes during radiotherapy treatment planning.
Number of subjects: 15
Study 12516955 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolterodine ER 4 mg once daily
Number of subjects: 1015